Login to Your Account



Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting

By Catherine Shaffer
Staff Writer

Monday, September 9, 2013

The FDA released briefing documents for Glaxosmithkline plc’s Anoro Ellipta (umeclidinium/vilanterol) inhaler product for chronic obstructive pulmonary disease (COPD) ahead of a scheduled advisory committee meeting on Sept. 10. The outlook for Anoro Ellipta appears to be smooth sailing, as the FDA’s clinical review found little to criticize in GSK’s submission.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription